TY - JOUR
T1 - FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD
AU - Kantarci, Kejal
AU - Boeve, Bradley F.
AU - Przybelski, Scott A.
AU - Lesnick, Timothy G.
AU - Chen, Qin
AU - Fields, Julie
AU - Schwarz, Christopher G.
AU - Senjem, Matthew L.
AU - Gunte, Jeffrey L.
AU - Jack, Clifford R.
AU - Min, Paul
AU - Jain, Manoj
AU - Migayawa, Toji
AU - Savica, Rodolfo
AU - Graff-Radford, Jonathan
AU - Botha, Hugo
AU - Jones, David T.
AU - Knopman, David S.
AU - Graff-Radford, Neill
AU - Ferman, Tanis J.
AU - Petersen, Ronald C.
AU - Lowe, Val J.
N1 - Publisher Copyright:
© 2021
PY - 2021/1
Y1 - 2021/1
N2 - Background and Purpose: Patients with dementia with Lewy bodies (DLB) are characterized by hypometabolism in the parieto–occipital cortex and the cingulate island sign (CIS) on 18F-fluorodeoxyglucose (FDG) PET. Whether this pattern of hypometabolism is present as early as the prodromal stage of DLB is unknown. We investigated the pattern of hypometabolism in patients with mild cognitive impairment (MCI) who progressed to probable DLB compared to MCI patients who progressed to Alzheimer's disease (AD) dementia and clinically unimpaired (CU) controls. Methods: Patients with MCI from the Mayo Clinic Alzheimer's Disease Research Center who underwent FDG PET at baseline and progressed to either probable DLB (MCI-DLB; n = 17) or AD dementia (MCI-AD; n = 41) during follow-up, and a comparison cohort of CU controls (n = 100) were included. Results: Patients with MCI-DLB had hypometabolism in the parieto-occipital cortex extending into temporal lobes, substantia nigra and thalamus. When compared to MCI-AD, medial temporal and posterior cingulate metabolism were preserved in patients with MCI-DLB, accompanied by greater hypometabolism in the substantia nigra in MCI-DLB compared to MCI-AD. In distinguishing MCI-DLB from MCI-AD at the maximum value of Youden's index, CIS ratio was highly specific (90%) but not sensitive (59%), but a higher medial temporal to substantia nigra ratio was both sensitive (94%) and specific (83%). Conclusion: FDG PET is a potential biomarker for the prodromal stage of DLB. A higher medial temporal metabolism and CIS ratio, and lower substantia nigra metabolism have additive value in distinguishing prodromal DLB and AD.
AB - Background and Purpose: Patients with dementia with Lewy bodies (DLB) are characterized by hypometabolism in the parieto–occipital cortex and the cingulate island sign (CIS) on 18F-fluorodeoxyglucose (FDG) PET. Whether this pattern of hypometabolism is present as early as the prodromal stage of DLB is unknown. We investigated the pattern of hypometabolism in patients with mild cognitive impairment (MCI) who progressed to probable DLB compared to MCI patients who progressed to Alzheimer's disease (AD) dementia and clinically unimpaired (CU) controls. Methods: Patients with MCI from the Mayo Clinic Alzheimer's Disease Research Center who underwent FDG PET at baseline and progressed to either probable DLB (MCI-DLB; n = 17) or AD dementia (MCI-AD; n = 41) during follow-up, and a comparison cohort of CU controls (n = 100) were included. Results: Patients with MCI-DLB had hypometabolism in the parieto-occipital cortex extending into temporal lobes, substantia nigra and thalamus. When compared to MCI-AD, medial temporal and posterior cingulate metabolism were preserved in patients with MCI-DLB, accompanied by greater hypometabolism in the substantia nigra in MCI-DLB compared to MCI-AD. In distinguishing MCI-DLB from MCI-AD at the maximum value of Youden's index, CIS ratio was highly specific (90%) but not sensitive (59%), but a higher medial temporal to substantia nigra ratio was both sensitive (94%) and specific (83%). Conclusion: FDG PET is a potential biomarker for the prodromal stage of DLB. A higher medial temporal metabolism and CIS ratio, and lower substantia nigra metabolism have additive value in distinguishing prodromal DLB and AD.
KW - Alzheimer's disease
KW - Cingulate island sign
KW - Demenia with Lewy bodies
KW - FDG PET
KW - Mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=85109435941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109435941&partnerID=8YFLogxK
U2 - 10.1016/j.nicl.2021.102754
DO - 10.1016/j.nicl.2021.102754
M3 - Article
C2 - 34252877
AN - SCOPUS:85109435941
SN - 2213-1582
VL - 31
JO - NeuroImage: Clinical
JF - NeuroImage: Clinical
M1 - 102754
ER -